missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SARS-CoV-2 Spike Protein (RBD) Chimeric Recombinant Human Monoclonal Antibody (Sb#16)

Description
This antibody recognizes and binds the SARS CoV 2 C-terminal receptor binding domain (RBD) located in the extracellular portion of the spike protein.
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.
Specifications
Specifications
| Antigen | SARS-CoV-2 Spike Protein (RBD) Chimeric |
| Applications | ELISA, Functional Assay, Inhibition Assays |
| Classification | Recombinant Monoclonal |
| Clone | Sb#16 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% ProClin 300 |
| Gene Alias | Coronavirus; COVID; Covid 19; COVID19; COVID-19; SARS; SARS Coronavirus; SARS CoV; SARS CoV2; SARS CoV-2; SARS Spike Protein; SARS-CoV2; SARS-CoV-2 |
| Host Species | Human |
| Immunogen | This clone was originally isolated in a form of a synthetic nanobody (sybody) via a 'target swap' selection procedure against RBD-vYFP using ribosomal display and against RBD-Fc fusion during phage display rounds. |
| Show More |